Medical Bulletin 30/April/2026

Here are the top medical news for today:

Study Finds Estrogen Loss After Menopause May Affect Heart Health via Gene Regulation

Menopause doesn’t just change hormones—it may quietly rewrite how the heart is regulated at a genetic level.

A new study from Virginia Tech scientists suggests that the rise in cardiovascular risk after menopause may be driven not only by falling estrogen, but by deeper changes in gene activity.

Published in Cells, the research highlights how declining estrogen levels can reshape the epigenome—the system that controls when genes are switched on or off. These epigenetic shifts may help explain why conditions like heart disease, diabetes, and metabolic disorders become more common in women after menopause.

For years, estrogen loss has been viewed as the primary trigger behind increased cardiovascular risk. But this study reframes the issue, showing that hormone decline may set off longer-lasting changes in gene regulation that affect multiple systems, including metabolism, inflammation, and vascular health.

The findings also suggest that commonly used treatments—such as lipid-lowering drugs, glucose-lowering medications like GLP-1 receptor agonists and SGLT2 inhibitors, and lifestyle interventions like diet and exercise—may work in part by influencing these gene-regulatory pathways. Importantly, cardiovascular disease remains the leading cause of death among women, and its risk rises sharply during the menopause transition.

While much of the current evidence comes from laboratory studies, researchers emphasize the need for more human-based research to fully understand these processes. Ongoing work is also exploring conditions like heart failure with preserved ejection fraction (HFpEF), which disproportionately affects postmenopausal women.

Ultimately, this research signals a shift in thinking—moving from a hormone-centric view to a broader understanding of how menopause reshapes the body at a molecular level, with important implications for future prevention and treatment strategies.

REFERENCE: Edwards, A., et al. (2026). Estrogen, Epigenetics, and Cardiometabolic Health: Mechanisms and Therapeutic Strategies in Postmenopausal Women. Cells. DOI: 10.3390/cells15060529. https://www.mdpi.com/2073-4409/15/6/529

Researchers Find Link Between Processed Foods, Attention Decline and Dementia Risk

Your brain may be snacking on more than just chips—it could be paying the price in focus and long-term health. A new study published in Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring links higher intake of ultra-processed foods (UPFs) to poorer attention and increased scores on a modifiable dementia-risk index.

UPFs—industrial formulations packed with refined ingredients, additives, and minimal whole foods—now make up a significant portion of modern diets. In this study of over 2,100 adults aged 40 to 70, UPFs accounted for about 41% of total energy intake. Common sources included sweetened drinks, packaged snacks, processed meats, and ready meals.

The findings revealed a subtle but consistent trend: as UPF intake increased, attention scores declined. A 10% rise in UPF consumption—roughly equivalent to adding a packet of chips daily—was associated with a small drop in attention performance. At the same time, scores on a dementia-risk index rose, suggesting a potential link between these foods and long-term brain health.

Interestingly, these associations persisted even after adjusting for overall diet quality, including adherence to healthier patterns like the Mediterranean diet. This suggests that the effects of UPFs may go beyond simply displacing nutritious foods—they may have independent impacts on the brain.

Researchers propose several possible explanations. UPFs are already known to affect cardiometabolic health, which contributes to dementia risk. They may also disrupt the gut microbiome, triggering inflammation through the gut-brain axis—a pathway increasingly linked to cognitive function.

However, the study does not prove cause and effect. Still, the results add to growing evidence that how food is processed—not just what it contains—matters for brain health.

As researchers call for long-term studies, one takeaway is already clear: small dietary shifts today could help protect cognitive function tomorrow.

REFERENCE: Cardoso, B. R., Steele, E., M., Brayner, B., et al (2026). Ultra-processed food intake, cognitive function, and dementia risk: A cross-sectional study of middle-aged and older Australian adults. Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring. DOI: https://doi.org/10.1002/dad2.70335. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.70335

Harvard Study Reveals Gut Bacteria May Influence Depression Risk via Inflammation

A hidden chemical hitchhiking on a gut bacterium may be quietly fueling inflammation—and possibly depression—inside the body. New research from Harvard Medical School sheds light on how a common microbe, Morganella morganii, could influence brain health through an unexpected molecular pathway.

Scientists have long suspected a link between the gut microbiome and mental health, but the exact mechanisms have remained unclear. This study, published in Journal of the American Chemical Society, provides one of the clearest explanations yet. Researchers discovered that an environmental chemical called diethanolamine (DEA)—found in many industrial and consumer products—can alter a molecule produced by M. morganii in the gut.

Normally, this bacterial molecule is harmless. But when DEA replaces part of its structure, it transforms into something far more active. The altered compound triggers the immune system, leading to the release of inflammatory proteins known as cytokines—especially interleukin-6. Elevated levels of IL-6 have already been linked to chronic inflammation and conditions like major depressive disorder.

This discovery strengthens the idea that, for some individuals, depression may not be purely psychological—it could also have an immune-driven component. If DEA-related changes can be detected in the body, they might serve as a biomarker to identify specific types of depression. In turn, treatments that target inflammation or immune pathways could offer new therapeutic options.

Importantly, researchers caution that this is an early step. The study does not prove that this mechanism directly causes depression, but it provides a compelling biological link worth further investigation.

Beyond mental health, the research highlights a broader concept: environmental chemicals and gut microbes may interact in ways that reshape human biology.

REFERENCE: Sunghee Bang, Yern-Hyerk Shin, Sung-Moo Park, Lei Deng, R. Thomas Williamson, Daniel B. Graham, Ramnik J. Xavier, Jon Clardy. Unusual Phospholipids from Morganella morganii Linked to Depression. Journal of the American Chemical Society, 2025; 147 (4): 2998 DOI: 10.1021/jacs.4c15158